Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti Tumor Activity of LBL-015 in Patients With Advanced Malignant Tumors

Next Previous
X
Search
Trial Profile

An Open-label, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti Tumor Activity of LBL-015 in Patients With Advanced Malignant Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LBL-015 (Primary)
  • Indications Carcinoma; Colorectal cancer; Gastric cancer; Nasopharyngeal cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Leads Biolabs

    • Most Recent Events

    • 04 Jun 2024 Preliminary results (n=25; data cutoff date: 25 Dec 2023) reporting safety and efficacy data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 13 May 2024 According to a Leads Biolabs media release, the company will present data from this study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting between May 31 to June 4, 2024 in Chicago.
    • 07 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top